- Home
- CGON vs EVT Comparison
CGON vs EVT Comparison
Compare CGON & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- EVT
- Stock Information
- Founded
- CGON 2010
- EVT 2003
- Country
- CGON United States
- EVT United States
- Employees
- CGON N/A
- EVT N/A
- Industry
- CGON
- EVT Finance Companies
- Sector
- CGON
- EVT Finance
- Exchange
- CGON NYSE
- EVT Nasdaq
- Market Cap
- CGON 2.0B
- EVT 1.7B
- IPO Year
- CGON 2024
- EVT N/A
- Fundamental
- Price
- CGON $26.91
- EVT $24.10
- Analyst Decision
- CGON Strong Buy
- EVT
- Analyst Count
- CGON 11
- EVT 0
- Target Price
- CGON $63.30
- EVT N/A
- AVG Volume (30 Days)
- CGON 979.0K
- EVT 115.5K
- Earning Date
- CGON 08-07-2025
- EVT 01-01-0001
- Dividend Yield
- CGON N/A
- EVT 8.32%
- EPS Growth
- CGON N/A
- EVT N/A
- EPS
- CGON N/A
- EVT 6.63
- Revenue
- CGON $662,000.00
- EVT $69,404,302.00
- Revenue This Year
- CGON N/A
- EVT N/A
- Revenue Next Year
- CGON $21,843.29
- EVT N/A
- P/E Ratio
- CGON N/A
- EVT $3.55
- Revenue Growth
- CGON 224.51
- EVT N/A
- 52 Week Low
- CGON $14.80
- EVT $19.20
- 52 Week High
- CGON $40.47
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- CGON 54.12
- EVT 53.98
- Support Level
- CGON $25.14
- EVT $24.12
- Resistance Level
- CGON $27.09
- EVT $24.35
- Average True Range (ATR)
- CGON 1.50
- EVT 0.20
- MACD
- CGON -0.04
- EVT -0.03
- Stochastic Oscillator
- CGON 53.56
- EVT 51.21
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.